litlas
Log inCreate account

Mario E. Lacouture

Active 2001–2025

144
Papers
23,682
Citations
88
h-index
141
i10-index

Citations

Citations per year for Mario E. Lacouture2002: 6 citations2004: 1 citations2005: 3 citations2006: 6 citations2007: 15 citations2008: 21 citations2009: 66 citations2010: 72 citations2011: 73 citations2012: 67 citations2013: 95 citations2014: 87 citations2015: 118 citations2016: 189 citations2017: 230 citations2018: 253 citations2019: 931 citations2020: 1,118 citations2021: 1,075 citations2022: 805 citations2023: 588 citations2024: 1,098 citations2025: 505 citations2026: 6 citations2003: no citations, so this year is not shown

Citation sources

Countries

World map of the countries and regions citing this authorUnited States: 2,462 citing papers, 26.4% of this breakdownChina: 1,067 citing papers, 11.4% of this breakdownItaly: 627 citing papers, 6.7% of this breakdownFrance: 490 citing papers, 5.3% of this breakdownGermany: 452 citing papers, 4.8% of this breakdownUnited Kingdom: 447 citing papers, 4.8% of this breakdownJapan: 329 citing papers, 3.5% of this breakdownSpain: 298 citing papers, 3.2% of this breakdownCanada: 289 citing papers, 3.1% of this breakdownAustralia: 267 citing papers, 2.9% of this breakdownNetherlands: 219 citing papers, 2.4% of this breakdownSwitzerland: 216 citing papers, 2.3% of this breakdown
0%26.4%Other 23.2%

Institutions

Fields

  • Medicine76.4%
  • Biochemistry, Genetics and Molecular Biology15.9%
  • Immunology and Microbiology3.9%
  • Engineering1%
  • Pharmacology, Toxicology and Pharmaceutics0.5%
  • Neuroscience0.4%
  • Other1.9%

Topics

  • Cancer Immunotherapy and Biomarkers12%
  • Colorectal Cancer Treatments and Studies4.3%
  • CAR-T cell therapy research3.2%
  • Melanoma and MAPK Pathways2.7%
  • Lung Cancer Treatments and Mutations2.7%
  • Immunotherapy and Immune Responses2.4%
  • Other72.7%

Coauthors

All papers

Open in search
  1. Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune checkpoint inhibitor-related adverse events

    Authors: Julie R. Brahmer, Hamzah Abu‐Sbeih, Paolo A. Ascierto, Jill Brufsky, Laura C. Cappelli, Frank B. Cortazar, David E. Gerber, Lamya Hamad, Eric Hansen, Douglas B. Johnson, Mario E. Lacouture, Gregory A. Masters, Jarushka Naidoo, Michele Nanni, Miguel‐Angel Perales, Igor Puzanov, Bianca Santomasso, Satish Shanbhag, Rajeev Sharma, Dimitra Skondra, Jeffrey A. Sosman, Michelle Turner, Marc S. Ernstoff - Journal for ImmunoTherapy of Cancer 2021 cited by 826

  2. Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group

    Authors: on behalf of the Society for Immunotherapy of Cancer Toxicity Management Working Group, Igor Puzanov, Adi Diab, K. Abdallah, Clifton O. Bingham, Cynthia F. Brogdon, Ramona Dadu, Lamya Hamad, Sungjun Kim, Mario E. Lacouture, Nicole R. LeBoeuf, Dan Lenihan, C.D. Onofrei, Vickie R. Shannon, Rajeev Sharma, Ann W. Silk, Dimitra Skondra, María E. Suarez‐Almazor, Yinghong Wang, Kathleen E. Wiley, Howard L. Kaufman, Marc S. Ernstoff - Journal for ImmunoTherapy of Cancer 2017 cited by 1,984

  3. Toxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodies

    Authors: Jarushka Naidoo, David B. Page, Bob T. Li, Louise C. Connell, Katja Schindler, Mario E. Lacouture, Michael A. Postow, Jedd D. Wolchok - Annals of Oncology 2015 cited by 1,463

  4. Immune checkpoint inhibitor–related dermatologic adverse events

    Authors: Amaris Geisler, Gregory S. Phillips, Dulce M. Barrios, Jennifer Wu, Donald Y.M. Leung, Andrea P. Moy, Jeffrey A. Kern, Mario E. Lacouture - Journal of the American Academy of Dermatology 2020 cited by 462

  5. First-in-Class ERK1/2 Inhibitor Ulixertinib (BVD-523) in Patients with MAPK Mutant Advanced Solid Tumors: Results of a Phase I Dose-Escalation and Expansion Study

    Authors: Ryan J. Sullivan, Jeffrey R. Infante, Filip Jankú, Deborah Jean Lee Wong, Jeffrey A. Sosman, Vicki L. Keedy, Manish R. Patel, Geoffrey I. Shapiro, James W. Mier, Anthony W. Tolcher, Andrea Wang‐Gillam, Mario Sznol, Keith T. Flaherty, Elizabeth I. Buchbinder, Richard D. Carvajal, Anna M. Varghese, Mario E. Lacouture, Antoni Ribas, Sapna P. Patel, Gary DeCrescenzo, Caroline M. Emery, Anna Groover, Saurabh Saha, Mary Varterasian, Dean J. Welsch, David M. Hyman, Bob T. Li - Cancer Discovery 2017 cited by 418

  6. Management of Immunotherapy-Related Toxicities, Version 1.2019, NCCN Clinical Practice Guidelines in Oncology

    Authors: John A. Thompson, Bryan J. Schneider, Julie R. Brahmer, Stephanie Andrews, Philippe Armand, Shailender Bhatia, Lihua E. Budde, Luciano J. Costa, Marianne Davies, David Dunnington, Marc S. Ernstoff, Matthew J. Frigault, Brianna Hoffner, Christopher Hoimes, Mario E. Lacouture, Frederick L. Locke, Matthew A. Lunning, Nisha Mohindra, Jarushka Naidoo, Anthony J. Olszanski, Olalekan O. Oluwole, Sandip Pravin Patel, Sunil Reddy, Mabel Ryder, Bianca Santomasso, Scott Shofer, Jeffrey A. Sosman, Momen M. Wahidi, Yinghong Wang, Alyse Johnson-Chilla, Jillian L. Scavone - Journal of the National Comprehensive Cancer Network 2019 cited by 560

  7. Efficacy of MEK inhibition in patients with histiocytic neoplasms

    Authors: Eli L. Diamond, Benjamin H. Durham, Gary A. Ulaner, Esther Drill, Justin J. Buthorn, Michelle Ki, Lillian Bitner, Hanna Cho, Robert J. Young, Jasmine H. Francis, Raajit K. Rampal, Mario E. Lacouture, Lynn A. Brody, Neval Özkaya, Ahmet Doǧan, Neal Rosen, Alexia Iasonos, Omar Abdel‐Wahab, David M. Hyman - Nature 2019 cited by 384

  8. Toxic Side Effects of Targeted Therapies and Immunotherapies Affecting the Skin, Oral Mucosa, Hair, and Nails

    Authors: Mario E. Lacouture, V. Sibaud - American Journal of Clinical Dermatology 2018 cited by 355

  9. Activating mutations in CSF1R and additional receptor tyrosine kinases in histiocytic neoplasms

    Authors: Benjamin H. Durham, Estibaliz Lopez Rodrigo, Jennifer Picarsic, David H. Abramson, Veronica Rotemberg, Steven De Munck, Erwin Pannecoucke, Sydney X. Lu, Alessandro Pastore, Akihide Yoshimi, Diana Mandelker, Ozge Ceyhan‐Birsoy, Gary A. Ulaner, Michael F. Walsh, Mariko Yabe, Kseniya Petrova‐Drus, Maria E. Arcila, Marc Ladanyi, David B. Solit, Michael F. Berger, David M. Hyman, Mario E. Lacouture, Caroline Erickson, Ruth Saganty, Michelle Ki, Ira J. Dunkel, Vicente Santa‐María López, Jaume Mora, Julien Haroche, Jean‐François Emile, Olivier Decaux, Frédéric Geissmann, Savvas N. Savvides, Alexander Drilon, Eli L. Diamond, Omar Abdel‐Wahab - Nature Medicine 2019 cited by 228

  10. Safety and Efficacy of Re-treating with Immunotherapy after Immune-Related Adverse Events in Patients with NSCLC

    Authors: Fernando C. Santini, Hira Rizvi, Andrew J. Plodkowski, Ai Ni, Mario E. Lacouture, Maya Gambarin‐Gelwan, Olivia Wilkins, Elizabeth Panora, Darragh Halpenny, Niamh M. Long, Mark G. Kris, Charles M. Rudin, Jamie E. Chaft, Matthew D. Hellmann - Cancer Immunology Research 2018 cited by 332

  11. Vemurafenib for BRAF V600–Mutant Erdheim-Chester Disease and Langerhans Cell Histiocytosis

    Authors: Eli L. Diamond, Vivek Subbiah, A. Craig Lockhart, Jean‐Yves Blay, Igor Puzanov, Ian Chau, Noopur Raje, Jürgen Wolf, Joseph P. Erinjeri, Jean Torrisi, Mario E. Lacouture, Elena Élez, Ferran Martínez-Valle, Benjamin H. Durham, Maria E. Arcila, Gary A. Ulaner, Omar Abdel‐Wahab, Bethany Pitcher, Martina Makrutzki, Todd Riehl, José Baselga, David M. Hyman - JAMA Oncology 2017 cited by 405

  12. Management of Dermatologic Events Associated With the Nectin-4-directed Antibody-Drug Conjugate Enfortumab Vedotin

    Authors: Mario E. Lacouture, Anisha B. Patel, Jonathan E. Rosenberg, Peter H. O’Donnell - The Oncologist 2022 cited by 141

  13. Diverse and Targetable Kinase Alterations Drive Histiocytic Neoplasms

    Authors: Eli L. Diamond, Benjamin H. Durham, Julien Haroche, Zhan Yao, Jing Ma, Sameer A. Parikh, Zhaoming Wang, John Choi, Eun Hee Kim, Fleur Cohen‐Aubart, Stanley Chun-Wei Lee, Yijun Gao, Jean‐Baptiste Micol, Patrick Campbell, Michael P. Walsh, Brooke E. Sylvester, Igor Dolgalev, Olga Aminova, Adriana Heguy, Paul Zappile, Joy Nakitandwe, Chezi Ganzel, James Dalton, David W. Ellison, Juvianee Estrada‐Veras, Mario E. Lacouture, William A. Gahl, Philip J. Stephens, Vincent A. Miller, Jeffrey S. Ross, Siraj M. Ali, Samuel Briggs, Omotayo Fasan, Jared Block, Sébastien Héritier, Jean Donadieu, David B. Solit, David M. Hyman, José Baselga, Filip Jankú, Barry S. Taylor, Christopher Y. Park, Zahir Amoura, Ahmet Doǧan, Jean‐François Emile, Neal Rosen, Tanja A. Grüber, Omar Abdel‐Wahab - Cancer Discovery 2015 cited by 533

  14. Treatment Outcomes of Immune-Related Cutaneous Adverse Events

    Authors: Gregory S. Phillips, Jennifer Wu, Matthew D. Hellmann, Michael A. Postow, Naiyer A. Rizvi, Azael Freites‐Martínez, Donald Chan, Stephen W. Dusza, Robert J. Motzer, Jonathan E. Rosenberg, Margaret K. Callahan, Paul B. Chapman, Larisa J. Geskin, Adriana T. Lopez, Vanessa A. Reed, Gabriella Fabbrocini, Maria Carmela Annunziata, Oluwaseun Kukoyi, Aliyah Pabani, Chih-Hsun Yang, Wen‐Hung Chung, Alina Markova, Mario E. Lacouture - Journal of Clinical Oncology 2019 cited by 235

  15. Characterisation and management of dermatologic adverse events to agents targeting the PD-1 receptor

    Authors: Viswanath Reddy Belum, Benjamin Benhuri, Michael A. Postow, Matthew D. Hellmann, Alexander M. Lesokhin, Neil H. Segal, Robert J. Motzer, Shenhong Wu, Klaus J. Busam, Jedd D. Wolchok, Mario E. Lacouture - European Journal of Cancer 2016 cited by 415

  16. A Pilot Study of Preoperative Single-Dose Ipilimumab and/or Cryoablation in Women with Early-Stage Breast Cancer with Comprehensive Immune Profiling

    Authors: Heather L. McArthur, Adi Diab, David B. Page, Jianda Yuan, Stephen B. Solomon, Virgilio Sacchini, Christopher Comstock, Jeremy C. Durack, Majid Maybody, Janice S. Sung, Arielle A. Ginsberg, Phillip Wong, Afşar Barlas, Zhiwan Dong, Chunjun Zhao, Brian Blum, Sujata Patil, Deirdre Neville, Elizabeth Comen, Elizabeth A. Morris, Alan Kotin, Edi Brogi, Yuetao Wen, Monica Morrow, Mario E. Lacouture, Padmanee Sharma, James P. Allison, Clifford A. Hudis, Jedd D. Wolchok, Larry Norton - Clinical Cancer Research 2016 cited by 224

  17. Alterations in PTEN and ESR1 promote clinical resistance to alpelisib plus aromatase inhibitors

    Authors: Pedram Razavi, Maura N. Dickler, Payal D. Shah, Weiyi Toy, David N. Brown, Helen Won, Bob T. Li, Ronglai Shen, Neil Vasan, Shanu Modi, Komal Jhaveri, Betty Ann Caravella, Sujata Patil, Pier Selenica, Stephen Zamora, Aimee Cowan, Elizabeth Comen, Andy Singh, Anne M. Covey, Michael F. Berger, Clifford A. Hudis, Larry Norton, Rebecca J. Nagy, Justin I. Odegaard, Richard B. Lanman, David B. Solit, Mark E. Robson, Mario E. Lacouture, Edi Brogi, Jorge S. Reis‐Filho, Mary Ellen Moynahan, Maurizio Scaltriti, Sarat Chandarlapaty - Nature Cancer 2020 cited by 162

  18. Beyond Steroids: Immunosuppressants in Steroid-Refractory or Resistant Immune-Related Adverse Events

    Authors: Jia Luo, Jason Beattie, Paige Fuentes, Hira Rizvi, Jacklynn V. Egger, Jeffrey A. Kern, Donald Y.M. Leung, Mario E. Lacouture, Mark G. Kris, Maya Gambarin, Bianca Santomasso, David M. Faleck, Matthew D. Hellmann - Journal of Thoracic Oncology 2021 cited by 109

  19. European recommendations for management of immune checkpoint inhibitors‐derived dermatologic adverse events. The EADV task force ‘Dermatology for cancer patients’ position statement

    Authors: Zoé Apalla, Vasiliki Nikolaou, Davide Fattore, Gabriella Fabbrocini, Azael Freites‐Martínez, Pietro Sollena, Mario E. Lacouture, Lukas Kraehenbuehl, Alexander Stratigos, Ketty Peris, Elizabeth Lazaridou, Bertrand Richert, Émmanuelle Vigarios, Julia Riganti, Barouyr Baroudjian, Angela Filoni, Roni P. Dodiuk‐Gad, Célèste Lebbé, V. Sibaud - Journal of the European Academy of Dermatology and Venereology 2021 cited by 99

  20. Regorafenib dose-optimisation in patients with refractory metastatic colorectal cancer (ReDOS): a randomised, multicentre, open-label, phase 2 study

    Authors: Tanios Bekaii‐Saab, Fang‐Shu Ou, Daniel H. Ahn, Patrick M. Boland, Kristen K. Ciombor, Erica N. Heying, Travis Dockter, Nisha L. Jacobs, Boris Pasche, James M. Cleary, Jeffrey P. Meyers, Rodwige J. Desnoyers, Jeannine S. McCune, Katrina S. Pedersen, Afsaneh Barzi, E. Gabriela Chiorean, Jeffrey A. Sloan, Mario E. Lacouture, Heinz‐Josef Lenz, Axel Grothey - The Lancet Oncology 2019 cited by 284

  21. Cutaneous keratoacanthomas/squamous cell carcinomas associated with neutralization of transforming growth factor β by the monoclonal antibody fresolimumab (GC1008)

    Authors: Mario E. Lacouture, John C. Morris, Donald P. Lawrence, Antoinette R. Tan, Thomas Olencki, Geoffrey I. Shapiro, Bruce J. Dezube, Jay A. Berzofsky, Frank J. Hsu, Joan Guitart - Cancer Immunology Immunotherapy 2015 cited by 150

  22. EGFR and MET Amplifications Determine Response to HER2 Inhibition in ERBB2 -Amplified Esophagogastric Cancer

    Authors: Francisco Sánchez-Vega, Jaclyn F. Hechtman, Pau Castel, Geoffrey Y. Ku, Yaelle Tuvy, Helen Won, Christopher J. Fong, Nancy Bouvier, Gouri J. Nanjangud, Joanne Soong, Efsevia Vakiani, Mark Schattner, David P. Kelsen, Robert A. Lefkowitz, Karen T. Brown, Mario E. Lacouture, Marinela Capanu, Marissa S. Mattar, Besnik Qeriqi, Fabiola Cecchi, Yuan Tian, Todd Hembrough, Rebecca J. Nagy, Richard B. Lanman, Steven M. Larson, Neeta Pandit‐Taskar, Heiko Schöder, Christine A. Iacobuzio–Donahue, David H. Ilson, Wolfgang Weber, Michael F. Berger, Elisa de Stanchina, Barry S. Taylor, Jason S. Lewis, David B. Solit, Jorge A. Carrasquillo, Maurizio Scaltriti, Nikolaus Schultz, Yelena Y. Janjigian - Cancer Discovery 2018 cited by 147

  23. First-line regorafenib with nivolumab and chemotherapy in advanced oesophageal, gastric, or gastro-oesophageal junction cancer in the USA: a single-arm, single-centre, phase 2 trial

    Authors: Samuel Cytryn, Ryan H. Moy, Darren Cowzer, Ronak Shah, Joanne F. Chou, Smita S. Joshi, Geoffrey Y. Ku, Steven B. Maron, Avni M. Desai, Jessica Yang, Ryan Sugarman, Devika Rao, Zoe Goldberg, Carmelina Charalambous, M. A. Lapshina, Ariel Antoine, Fiona Socolow, Nikhil Trivedi, Marinela Capanu, Hans Gerdes, Mark Schattner, Marc Simmons, Mario E. Lacouture, Viktoriya Paroder, Laura H. Tang, Jinru Shia, David H. Ilson, David B. Solit, Michael F. Berger, Yelena Y. Janjigian - The Lancet Oncology 2023 cited by 45

  24. Mechanisms of cutaneous toxicities to EGFR inhibitors

    Authors: Mario E. Lacouture - Nature reviews. Cancer 2006 cited by 776